Border to Coast Pensions Partnership Ltd Boosts Stake in Zoetis Inc. $ZTS

Border to Coast Pensions Partnership Ltd grew its holdings in Zoetis Inc. (NYSE:ZTS) by 7.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 232,421 shares of the company’s stock after purchasing an additional 16,666 shares during the period. Border to Coast Pensions Partnership Ltd owned approximately 0.05% of Zoetis worth $34,008,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Savvy Advisors Inc. increased its position in shares of Zoetis by 54.0% in the 2nd quarter. Savvy Advisors Inc. now owns 3,177 shares of the company’s stock valued at $495,000 after purchasing an additional 1,114 shares during the last quarter. Chicago Partners Investment Group LLC lifted its position in shares of Zoetis by 67.0% during the 2nd quarter. Chicago Partners Investment Group LLC now owns 4,886 shares of the company’s stock worth $750,000 after purchasing an additional 1,961 shares during the last quarter. Nordea Investment Management AB grew its stake in shares of Zoetis by 10.0% during the second quarter. Nordea Investment Management AB now owns 2,356,166 shares of the company’s stock worth $368,245,000 after purchasing an additional 214,889 shares in the last quarter. CIBC Asset Management Inc grew its stake in shares of Zoetis by 4.3% during the third quarter. CIBC Asset Management Inc now owns 251,495 shares of the company’s stock worth $36,745,000 after purchasing an additional 10,434 shares in the last quarter. Finally, Shell Asset Management Co. increased its holdings in Zoetis by 58.1% in the second quarter. Shell Asset Management Co. now owns 9,890 shares of the company’s stock valued at $1,542,000 after buying an additional 3,636 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Performance

Shares of ZTS opened at $126.69 on Thursday. The company’s 50 day simple moving average is $124.00 and its 200-day simple moving average is $136.62. The firm has a market cap of $55.83 billion, a PE ratio of 21.33, a price-to-earnings-growth ratio of 2.11 and a beta of 0.96. Zoetis Inc. has a 12-month low of $115.25 and a 12-month high of $177.40. The company has a current ratio of 3.64, a quick ratio of 2.28 and a debt-to-equity ratio of 1.31.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The firm had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.42 billion. During the same quarter in the prior year, the business earned $1.58 EPS. Zoetis’s quarterly revenue was up .5% compared to the same quarter last year. As a group, equities analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 3rd. Investors of record on Tuesday, January 20th will be issued a dividend of $0.53 per share. This is an increase from Zoetis’s previous quarterly dividend of $0.50. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date of this dividend is Tuesday, January 20th. Zoetis’s dividend payout ratio is 35.69%.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Stifel Nicolaus decreased their price target on Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a report on Tuesday, November 18th. Barclays started coverage on shares of Zoetis in a research report on Monday, December 8th. They set an “equal weight” rating and a $136.00 price objective for the company. BTIG Research restated a “buy” rating and issued a $160.00 target price on shares of Zoetis in a report on Wednesday, December 3rd. Wall Street Zen upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, January 23rd. Finally, HSBC set a $140.00 price target on shares of Zoetis in a research report on Wednesday, December 10th. Five research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $152.45.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.